Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Early-stage diagnosis marker for aorta disease and application thereof

An early diagnosis, aortic technology, applied in biological testing, material testing products, etc., can solve the problems of poor specificity, high sensitivity, D-dimer cannot be used as a biochemical marker for the diagnosis of AAD, etc. The effect of testing cost economy

Inactive Publication Date: 2012-07-11
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF6 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the characteristics of high sensitivity and poor specificity, D-dimer cannot be used as a biochemical marker for the diagnosis of AAD.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Early-stage diagnosis marker for aorta disease and application thereof
  • Early-stage diagnosis marker for aorta disease and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Example 1: Screening of Lumican protein

[0015] Firstly, the serum of 10 patients with AAD was collected, and the serum of 10 normal healthy people was used as the normal control, and the serum of 10 patients with acute myocardial infarction was used as the disease control. The isobaric tags for relative and absolute quantitation (iTRAQ) technique Get screened. It was found that the expression of Lumican in the serum of AAD patients was 3.6311 times that of healthy people.

Embodiment 2

[0016] Embodiment 2: ELISA kit and detection method for detecting LUMICAN

[0017] 1. The ELISA kit for detecting LUMICAN includes: enzyme-linked plate; Lumican standard; sample diluent; biotin-labeled antibody diluent; horseradish peroxidase-labeled avidin diluent; biotin-labeled Lumican antibody; enzyme-labeled avidin; substrate solution; concentrated washing solution; stop solution (Human basement membrane glycan / lumen protein (LUM) enzyme-linked immunoassay kit (No.CSB) produced by Wuhan Huamei Bioengineering Co., Ltd. -E09797h) provided).

[0018] 2. Detection specific steps:

[0019] 1) Collection and storage of specimens: within 2 hours at room temperature, centrifuge the whole blood specimen at 4500 rpm for 20 minutes, take the supernatant, and test immediately; you can also store the supernatant at -80°C for testing after thawing.

[0020] 2) Dilution of the standard: Centrifuge the standard at 8000rpm for 30 seconds. Dilute each bottle with sample diluent to 1ml...

Embodiment 3

[0033] Samples were taken from 118 patients with acute chest pain, including 54 cases of AAD, 7 cases of aortic aneurysm, 5 cases of aortic intramural hematoma, 37 cases of acute coronary syndrome, 5 cases of pulmonary embolism, 4 cases of pulmonary and pleural inflammation, digestive 2 cases of systemic diseases and 4 cases of chest pain caused by other reasons were verified by the method described in Example 2. The results showed that the serum Lumican concentrations in non-AD patients were all lower than 1.5ng / ml, 17 of the 54 patients with acute aortic dissection (AAD) had Lumican concentrations higher than 1.5ng / ml, and 7 patients with aortic aneurysm There were 5 cases with Lumican concentration higher than 1.5ng / ml (see figure 1 ). When the concentration of Lumican in patients with chest pain is higher than 1.5ng / ml, the accuracy rate of diagnosing aortic disease is 100%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an early-stage diagnosis marker for an aorta disease and application thereof. The application mainly relates to the fact the lumican serves as the early-stage diagnosis marker for the aorta disease in preparation of an early-stage diagnosis reagent for the aorta disease. The early-stage diagnosis marker for the aorta disease and the application of the marker has the advantages that blood serum lumican detection to a chest pain patient is fast in detection process, economical in detection cost and wound-free to the patient.

Description

technical field [0001] The invention relates to a marker for early diagnosis of aortic disease and its application. Background technique [0002] Basement membrane glycan (Lumican) is a matrix protein present in the aortic media, which is released into the blood during acute aortic injury, and its serum concentration can be used as a specific indicator for early judgment of acute aortic disease (AD). [0003] Acute aortic disease (AD) includes acute aortic dissection (AAD), aortic intramural hematoma (IMH), thoracoabdominal aortic aneurysm (TAA / AAA), etc. Its annual incidence rate is about 25-30 per million, and the onset is acute and serious. According to literature reports, the missed diagnosis rate of AAD in the emergency room can be as high as 50%, and 25% of AAD diagnoses are confirmed only through postmortem autopsy. In addition to factors such as severe disease, poor blood pressure control, and disease progression, the cause of death caused by AAD is the delay and d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
Inventor 姚晨玲童朝阳顾国嵘
Owner ZHONGSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com